Pacific Biosciences Of California (PACB) Total Current Liabilities (2010 - 2026)
Pacific Biosciences Of California (PACB) posted quarterly Total Current Liabilities of $65.4 million for Q1 2026, down 1.87% year-over-year from $66.6 million in Q1 2025, and down 10.26% quarter-over-quarter from $72.8 million in Q4 2025.
Pacific Biosciences Of California (PACB) Total Current Liabilities (2010 - 2026) Analysis & Trends
Pacific Biosciences Of California's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $65.4 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 1.87% year-over-year to $65.4 million; the TTM figure through Mar 2026 stood at $65.4 million (down 1.87% YoY), while the FY2025 annual figure was $72.8 million, up 9.85% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $65.4 million, down from $72.8 million in the prior quarter.
- The five-year high for Total Current Liabilities was $271.4 million in Q2 2023, with the low at $59.8 million in Q2 2025.
- The 5-year median for Total Current Liabilities is $73.0 million (2024), against an average of $112.5 million.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities surged 335.46% in 2023, then sank 72.54% in 2024.
- Pacific Biosciences Of California's Total Current Liabilities stood at $263.3 million in 2022, then slumped by 63.91% to $95.0 million in 2023, then plunged by 30.23% to $66.3 million in 2024, then rose by 9.85% to $72.8 million in 2025, then dropped by 10.26% to $65.4 million in 2026.
- Business Quant data shows PACB's Total Current Liabilities at $65.4 million in Q1 2026, $72.8 million in Q4 2025, and $63.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.51 Bn | 194.91 Bn | 7.27 Bn | 17.81 Bn |
| 2 | Stryker | 129.96 Bn | 126.48 Bn | 4.50 Bn | 6.68 Bn |
| 3 | Medtronic | 120.18 Bn | 110.96 Bn | 6.41 Bn | 11.66 Bn |
| 4 | Boston Scientific | 74.28 Bn | 73.74 Bn | 3.85 Bn | 6.43 Bn |
| 5 | Edwards Lifesciences | 52.75 Bn | 48.50 Bn | 1.35 Bn | 1.51 Bn |
| 6 | Dexcom | 34.67 Bn | 32.73 Bn | 830.00 Mn | 2.36 Bn |
| 7 | GE HealthCare Technologies | 34.23 Bn | 32.12 Bn | 2.18 Bn | 8.30 Bn |
| 8 | Koninklijke Philips | 26.46 Bn | 23.14 Bn | 4.55 Bn | 8.63 Bn |
| 9 | Steris | 23.30 Bn | 22.82 Bn | 684.20 Mn | 1.28 Bn |
| 10 | Pacific Biosciences Of California | 397.64 Mn | 160.77 Mn | 12.64 Mn | 68.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 68.81 Mn |
| Mar 31, 2026 | 65.36 Mn |
| Dec 31, 2025 | 72.83 Mn |
| Sep 30, 2025 | 63.21 Mn |
| Jun 30, 2025 | 59.75 Mn |
| Mar 31, 2025 | 66.60 Mn |
| Dec 31, 2024 | 66.30 Mn |
| Sep 30, 2024 | 60.00 Mn |
| Jun 30, 2024 | 78.39 Mn |
| Mar 31, 2024 | 72.95 Mn |
| Dec 31, 2023 | 95.03 Mn |
| Sep 30, 2023 | 183.96 Mn |
| Jun 30, 2023 | 271.41 Mn |
| Mar 31, 2023 | 265.67 Mn |
| Dec 31, 2022 | 263.34 Mn |
| Sep 30, 2022 | 81.65 Mn |
| Jun 30, 2022 | 84.40 Mn |
| Mar 31, 2022 | 61.01 Mn |
| Dec 31, 2021 | 71.71 Mn |
| Jun 30, 2021 | 45.43 Mn |